Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience CorpfiledCriticalRinat Neuroscience Corp
Publication of AR102872A1publicationCriticalpatent/AR102872A1/en
Anticuerpos antagonistas que se fijan a la proteína de muerte celular programada 1 (PD-1) y métodos para usarlos. Los anticuerpos anti-PD-1 se pueden usar terapéuticamente solos o en combinación con otros tratamientos para tratar el cáncer y otras enfermedades. Célula huésped, ADN, vector, método para producir el anticuerpo, composición farmacéutica.Antagonist antibodies that bind to programmed cell death protein 1 (PD-1) and methods to use them. Anti-PD-1 antibodies can be used therapeutically alone or in combination with other treatments to treat cancer and other diseases. Host cell, DNA, vector, method for producing the antibody, pharmaceutical composition.
ARP150103926A2014-12-092015-12-01
ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
AR102872A1
(en)
antibody, polynucleotide, vector, cell, methods to express the antibody, to treat a condition associated with pd-1 and to treat a condition in a subject, kit, pharmaceutical composition and use of the antibody
ANTIBODIES AGAINST THE ORPHANE RECEPTOR SIMILAR TO THE THIROSINE QUINASE 1 (ANTI-ROR1) RECEPTOR, BISPECIFIC ANTIBODIES THAT JOIN ROR1 AND THE CD3 ANTIGEN, AND METHODS FOR TREATMENT OF CANCER